Hospital Anxiety and Depression Scale (HADS) accuracy in cancer patients

Annunziata, Maria Antonietta; Muzzatti, Barbara; Bidoli, Ettore; Flaiban, Cristiana; Bomben, Francesca; Piccinin, Marika; Gipponi, Katiuscia Maria; Mariutti, Giulia; Busato, Sara; Mella, Sara

doi:10.1007/s00520-019-05244-8

Cited by 187 publications

(131 citation statements)

References 23 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…The HADS is a 14-item self-report questionnaire that was originally developed to evaluate the presence of anxiety and depression in the context of a medical non-psychiatric outpatient clinic over the preceding week [ 4 , 12 ] and is nowadays one of the most used tools to evaluate anxiety and depression in cancer patients as a first screening [ 4 , 13 , 14 , 15 ]. It is easy with a rapid administration procedure and it has a good reliability [ 16 ], as we found in the present study (Cronbach α: 0.898). HADS is divided into two 7-item subscales, HADS-A for anxious symptomatology (an example of the anxiety sub-scale item is: “I feel tense or ‘wound up’”) and HADS-D for depressive symptomatology (an example of the anxiety sub-scale item is: “I still enjoy the things I used to enjoy”).…”

Section: Methodssupporting

confidence: 70%

Anxiety and Depression in Women Newly Diagnosed with Breast Cancer and Waiting for Surgery: Prevalence and Associations with Socio-Demographic Variables

et al. 2021

View full text Add to dashboard Cite

Background and Objectives: Cancer is a threatening-life disease with a significant psychological burden. The psychological morbidity varies according to the phases of the illness and is influenced by multiple socio-demographic factors, that are useful to consider in order to identify the categories of patients most at risk of developing psychiatric disorders. The present study analyzes, in a sample of women newly diagnosed with breast cancer, the relationships between their levels of anxiety and depression and several socio-demographic characteristics. The study was cross-sectional. Materials and Methods: Four hundred and seventy eight women newly diagnosed with breast cancer completed the Hospital Anxiety and Depression Scale during the pre-surgical phase. Results: Findings show that almost 40% of the sample had clinically relevant anxious symptoms and about a quarter of the sample had significant depressive symptoms. Their prevalence was higher in widows. Moreover, depressive symptoms were higher in older women and anxious symptoms were higher in patients with a lower educational level. In the pre-surgical phase, women can suffer from clinically relevant anxiety and depression, especially the widows, older women, and women with a lower educational level. Conclusions: Identifying the most psychologically vulnerable patients, due to specific socio-demographic characteristics, is essential in order to provide adequate psycho-oncological treatments to the categories of patients, who are most at risk of developing psychopathological concerns.

show abstract

Section: Methodssupporting

confidence: 70%

Anxiety and Depression in Women Newly Diagnosed with Breast Cancer and Waiting for Surgery: Prevalence and Associations with Socio-Demographic Variables

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Our result is in line of previous meta-analysis on depression and anxiety in COVID‐19 patients [ 54 ] that showed higher depression and anxiety prevalence values from GAD-7 and SAS compared with HADS‐A, and they mentioned that it is due to lower cut-off values for PHQ‐9, GAD‐7, SAS and SDS for identifying depression and anxiety symptoms. Knowledge on comparing different method assessments in evaluating anxiety and depression in patients with cancer is still not well documented; however, some evidence suggested that HADS is a better option for identifying anxious and depressive states in cancer patients during clinical practice compared with other tools because of better compliance of patients, shorter consumption of time, good correlation with clinical features, good psychometric properties and specific of medical settings [ 55 – 58 ].…”

Section: Discussionmentioning

confidence: 99%

Depression and Anxiety Among Patients with Cancer During COVID-19 Pandemic: A Systematic Review and Meta-analysis

Ayubi

Bashirian

Khazaei

2021

J Gastrointest Canc

View full text Add to dashboard Cite

“…This scale has demonstrated solid psychometric properties (Connor and Davidson, 2001). As regards the other scales aimed at measuring the symptoms of anxiety, depression, and stress, validated and common scales used in internal medical contexts, in particular the HADS and the SCL-90, were administered in the considered studies (Wang et al, 2017;Annunziata et al, 2020). One of the limits of our review was the exclusion of non-English articles.…”

Section: Discussionmentioning

confidence: 99%

EMDR in Cancer Patients: A Systematic Review

Pomeri

Salvia²,

Carletto³

et al. 2021

Front. Psychol.

View full text Add to dashboard Cite

Background: Psychological distress is common among patients with cancer, with severe consequences on their quality of life. Anxiety and depression are the most common clinical presentation of psychological distress in cancer patients, but in some cases cancer may represent a traumatic event resulting in posttraumatic stress disorder (PTSD). Currently, Eye Movement Desensitization and Reprocessing (EMDR) therapy is considered an evidence-based treatment for PTSD, but recent studies also showed its effectiveness for anxiety and depression. The aim of the present systematic review is to summarize the current literature on the effect of EMDR on cancer-related psychological distress.Methods: A literature search was conducted for peer-reviewed articles about “EMDR” and “cancer patients” in the following electronic databases: PubMed, MEDLINE, Science Direct, Google Scholar, and Cochrane library.Results: Our search identified 7 studies in which EMDR was used with a total of 140 cancer patients. The psychiatric diagnosis was PTSD in 3 studies. Otherwise, the diagnosis concerned the anxious and depressive disorder spectrum. Overall, EMDR treatment schedules used were highly heterogeneous, with a different number of sessions (from 2 to 12) and a different duration of therapy (up to 4 months). However, across all studies analyzed EMDR therapy was judged to be adequate in reducing symptoms of psychological distress in this population.Conclusions: According to the results of our analysis, the level of evidence regarding EMDR efficacy in cancer patients is limited by the scarcity of studies and their low methodological quality. Although better quality research is needed, available data suggest that EMDR could be a promising treatment for psychological distress in patients with cancer.

show abstract

Hospital Anxiety and Depression Scale (HADS) accuracy in cancer patients

Cited by 187 publications

References 23 publications

Anxiety and Depression in Women Newly Diagnosed with Breast Cancer and Waiting for Surgery: Prevalence and Associations with Socio-Demographic Variables

Anxiety and Depression in Women Newly Diagnosed with Breast Cancer and Waiting for Surgery: Prevalence and Associations with Socio-Demographic Variables

Depression and Anxiety Among Patients with Cancer During COVID-19 Pandemic: A Systematic Review and Meta-analysis

EMDR in Cancer Patients: A Systematic Review

Contact Info

Product

Resources

About